Kei Kanie
Overview
Explore the profile of Kei Kanie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hisada T, Imai Y, Takemoto Y, Kanie K, Kato R
J Biosci Bioeng
. 2024 Mar;
137(6):453-462.
PMID: 38472072
Monoclonal antibodies (mAbs) represent a significant segment of biopharmaceuticals, with the market for mAb therapeutics expected to reach $200 billion in 2021. Chinese Hamster Ovary (CHO) cells are the industry...
2.
Ohno T, Suenaga H, Yamawaki-Ogata A, Kanie K, Kato R, Uto K, et al.
Interdiscip Cardiovasc Thorac Surg
. 2023 Nov;
37(5).
PMID: 37930044
Objectives: The use of bone wax (BW) is controversial for sternal haemostasis because it increases the risk of wound infection and inhibits bone healing. We developed new waxy bone haemostatic...
3.
Uesaka K, Oka H, Kato R, Kanie K, Kojima T, Tsugawa H, et al.
J Biosci Bioeng
. 2022 Sep;
134(5):363-373.
PMID: 36127250
Recent advances have led to the emergence of highly comprehensive and analytical approaches, such as omics analysis and high-resolution, time-resolved bioimaging analysis. These technologies have made it possible to obtain...
4.
Imai Y, Iida M, Kanie K, Katsuno M, Kato R
Sci Rep
. 2022 Jun;
12(1):9296.
PMID: 35710681
Label-free image analysis has several advantages with respect to the development of drug screening platforms. However, the evaluation of drug-responsive cells based exclusively on morphological information is challenging, especially in...
5.
Horie M, Yamano-Adachi N, Kawabe Y, Kaneoka H, Fujita H, Nagamori E, et al.
J Biosci Bioeng
. 2022 Apr;
133(6):509-514.
PMID: 35382990
The industrial use of living organisms for bioproduction of valued substances has been accomplished mostly using microorganisms. To produce high-value bioproducts such as antibodies that require glycosylation modification for better...
6.
Wang Y, Kanie K, Takezawa T, Horikawa M, Kaneko K, Sugimoto A, et al.
Carbohydr Polym
. 2022 Mar;
285:119223.
PMID: 35287853
During wound regeneration, both cell adhesion and adhesion-inhibitory functions must be controlled in parallel. We developed a membrane with dual surfaces by merging the properties of carboxymethyl cellulose (CMC) and...
7.
Imai Y, Kanie K, Kato R
Inflamm Regen
. 2022 Jan;
42(1):8.
PMID: 35093181
Background: Within the extensively developed therapeutic application of mesenchymal stem cells (MSCs), allogenic immunomodulatory therapy is among the promising categories. Although donor selection is a critical early process that can...
8.
Yamashita H, Fujitani M, Shimizu K, Kanie K, Kato R, Honda H
ACS Biomater Sci Eng
. 2021 Jan;
6(11):6117-6125.
PMID: 33449638
We developed a method for efficiently activating functional peptides with a large structural contribution using the peptide-searching method with machine learning. The physicochemical properties of the amino acids were employed...
9.
Takemoto Y, Imai Y, Kanie K, Kato R
J Biosci Bioeng
. 2020 Oct;
131(2):198-206.
PMID: 33121889
With rapid advances in cell therapy, technologies enabling both consistency and efficiency in cell manufacturing are becoming necessary. Morphological monitoring allows practical quality maintenance in cell manufacturing facilities, but relies...
10.
Shirai K, Kato H, Imai Y, Shibuta M, Kanie K, Kato R
Regen Ther
. 2020 May;
14:205-214.
PMID: 32435672
Because of the growing demand for human cell spheroids as functional cellular components for both drug development and regenerative therapy, the technology to non-invasively evaluate their quality has emerged. Image-based...